Rapidly progressive glomerulonephritis laboratory findings

Revision as of 20:27, 7 May 2018 by Aelsaiey (talk | contribs)
Jump to navigation Jump to search

Rapidly progressive glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rapidly progressive glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray Findings

CT-scan Findings

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rapidly progressive glomerulonephritis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rapidly progressive glomerulonephritis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rapidly progressive glomerulonephritis laboratory findings

CDC on Rapidly progressive glomerulonephritis laboratory findings

Rapidly progressive glomerulonephritis laboratory findings in the news

Blogs on Rapidly progressive glomerulonephritis laboratory findings

Directions to Hospitals Treating Rapidly progressive glomerulonephritis

Risk calculators and risk factors for Rapidly progressive glomerulonephritis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Laboratory Findings

Blood Work-Up

  • Complete blood count (CBC) differential and platelet count
  • Serum electrolytes
  • Creatinine and blood urea nitrogen (BUN)
  • Lactate dehydrogenase (LDH)
  • Creatine phosphokinase (CPK)
  • Liver function tests
  • Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)
  • Antinuclear antibody (ANA)
  • Anti-GBM antibodies
  • ANCA
  • Cryoglobulins
  • HBV and HCV titers
  • Complement C3 and C4 levels
  • Serum protein electrophoresis

Anemia is common among patient with RPGN, mostly due to renally impaired production of erythropoietin or GI bleeding. Eosinophilia may be seen in a subset of patients with Churg-Strauss disease.

Patients with RPGN may show formation of immune complexes and cryoglobulins. Complement C3 levels is usually low in immune-complex mediated RPGN. The presence of ANCA and anti-GBM is variable; their presence is important for classification of disease and further management planning. Anti-GBM levels is However, anti-GBM antibody level is not prognostic and is not associated with disease activity.[1] On the contrary, literature regarding ANCA-associated glomerulonephritis suggests that levels of ANCA is associated with disease activity and may be used as an index for such purposes.[2][3][4]

ESR and CRP may be elevated and are correlated with the level of inflammation and thus activity of the disease.

Urine Work-Up

  • Urinalysis
  • Urinary protein electrophoresis

Patients with RPGN do not usually have a full-blown picture of nephrotic syndrome; Nephrotic syndrome only occurs in less than 30% of cases.[1] Proteinuria, if present, is usually mild to moderate. Hematuria of glomerular type with dysmorphic red blood cells is usually present on urinalysis and associated with red cell casts. Mild to moderate leukocyturia may be seen and other casts, such as epithelial cell leukocyte, or fatty casts. Urinary findings in RPGN are important features that not only favor diagnostic work-up, but also follow-up and therapeutic effectiveness.

Kidney Ultrasound

Kidney ultrasound is usually done during diagnostic biopsy. Due to its rapid progression, renal biopsy usually shows normal-sized kidneys. Although the test is not diagnostic, its non-invastive nature and the necessity to rule out other etiologies of renal impairment are both in favor of performing a renal ultrasound.

Kidney Biopsy

An ultrasound or CT-guided kidney biopsy is the only gold standard to diagnose RPGN and determine prognosis of the disease. The pathological hallmark of RPGN is presence of epithelial crescents in the Bowman’s capsule with or without endocapillary proliferation.[5] The extent of fibrous crescents along the glomerulus are considered a poor prognostic element.


References

  1. 1.0 1.1 Hricik DE, Chung-Park M, Sedor JR (1998). "Glomerulonephritis". N Engl J Med. 339 (13): 888–99. doi:10.1056/NEJM199809243391306. PMID 9744974.
  2. van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA; et al. (1985). "Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis". Lancet. 1 (8426): 425–9. PMID 2857806.
  3. Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF; et al. (1989). "Association between active Wegener's granulomatosis and anticytoplasmic antibodies". Arch Intern Med. 149 (11): 2461–5. PMID 2684074.
  4. Falk RJ, Hogan S, Carey TS, Jennette JC (1990). "Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network". Ann Intern Med. 113 (9): 656–63. PMID 2221646.
  5. Cunningham RJ, Gilfoil M, Cavallo T, Brouhard BH, Travis LB, Berger M; et al. (1980). "Rapidly progressive glomerulonephritis in children: a report of thirteen cases and a review of the literature". Pediatr Res. 14 (2): 128–32. doi:10.1203/00006450-198002000-00012. PMID 7360526.

Template:WH Template:WS